Yasa, Joe
Reed, Claudia E.
Bournazos, Adam M.
Evesson, Frances J.
Pang, Ignatius
Graham, Mark E.
Wark, Jesse R.
Nijagal, Brunda
Kwan, Kim H.
Kwiatkowski, Thomas
Jung, Rachel
Weisleder, Noah
Cooper, Sandra T.
Lemckert, Frances A.
Funding for this research was provided by:
Jain Foundation
National Health and Medical Research Council (APP1103618, APP1136197)
Article History
Received: 17 August 2022
Accepted: 3 November 2022
First Online: 18 January 2023
Declarations
:
: All animal procedures were conducted in accordance with the guidelines of the Australian National Health and Medical Research Council Australia and approved by the animal ethics committee at the Children’s Hospital at Westmead and Children’s Medical Research Institute (protocol no. CMRI/CHW-K344). Dysferlin deficient BLAJ mice (B6.A-<i>Dysf</i><sup><i>prmd</i></sup>/GeneJ) were obtained from the Animal Resources Centre (ARC), Murdoch, Western Australia. Dysferlin exon 40a knockout (40aKO) mice were created and bred in house in a pathogen-free animal care facility at the Children’s Hospital at Westmead. Wildtype (WT) control C57BL/6 mice were bred in house or sourced from the ARC. All mice were kept in microisolator cages on a 12-h light/dark cycle, under standard conditions with free access to drinking water and rat and mouse chow (Specialty Feeds, Glen Forrest, Australia).
: Sandra T. Cooper is director and shareholder of Frontier Genomics Pty Ltd (Australia). STC currently receives no consultancy fees or other remuneration for this role. Frontier Genomics has no current financial interests that will benefit from publication of these data. 40aKO mouse lines have been provided to Sarepta Therapeutics under license from the University of Sydney and Sydney Children’s Hospitals Network. The remaining authors have no competing interests to declare.